redefining-care_one-color

redefining-care_one-color

Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.

Learn more »

Uterine Fibroids

An estimated 5 million people in the U.S. suffer from symptoms of uterine fibroids.

Learn more »

Prostate Cancer

Approximately 3 million people alive today in the U.S. have been diagnosed with prostate cancer.

Learn more »

TRANSFORMATIVE ADVOCACY

transformative-advocacy

We’re partnering with cross-sector coalitions to fight stigma, raise awareness, and empower people with information.

PURPOSE-DRIVEN SCIENCE

purpose-driven

Myovant is developing innovative medicines that hold promise to improve people’s lives.

View our pipeline

On Twitter

Tweets by Myovant

News

1 Jun 2021

Myovant Sciences to Present at Upcoming Investor Conferences

26 May 2021

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

21 May 2021

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

11 May 2021

Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021

View more news

Events

17 Jun 2021

JMP Securities Life Sciences Conference

8 Jun 2021

Goldman Sachs 42nd Annual Global Healthcare Conference

28 May 2021

MYFEMBREE FDA Approval Conference Call

11 May 2021

Myovant Sciences Q4 2020 Earnings Conference Call

View more events

You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.